Aortic valve stenosis (AVS) is associated with significant morbidity and mortality, especially in the presence of symptoms and echocardiographic signs of left ventricular remodelling (i.e. increase in left ventricular mass, left ventricular dilation, and systolic dysfunction). Reninangiotensin system inhibitors (RASi) attenuate cardiac remodelling in various conditions, but the safety and efficacy of RASi in AVS is unsure. We performed a systematic review and meta-analysis to address these issues. We identified three smaller randomized clinical trials and five observational studies eligible for inclusion (PubMed, EMBASE, and Cochrane library search criteria: aortic stenosis, aortic valve, angiotensin-converting enzyme inhibitor in different combinations, published in English at any time up to 1 April 2016). Our analyses suggested that use of RASi was safe, with no observed increase in mortality risk [576/3389 patients receiving RASi vs. 1118/4384 controls died; relative risk 0.93 (95% confidence interval 0.78-1.11), P ¼ 0.44]. Use of RASi was also observed to lower the risk of aortic valve replacement (AVR) surgery [67/2913 patients with RASi vs. 154/3666 controls underwent AVR; relative risk 0.68 (95% confidence interval 0.51-0.91), P ¼ 0.01]. In current clinical practice (based on published literature; mainly observational studies
Introduction
Aortic valve stenosis (AVS) is the most common form for valvular heart disease in the Western world and comprises one of the major cardiovascular morbidities among the elderly. It is a vascular degenerative disorder that shares pathophysiology with atherosclerotic heart disease and the prevalence among elderly has been reported to be around 2-7%. 1 Significant risk factors for AVS include hypertension, high levels of low-density lipoprotein cholesterol, diabetes, lowgrade inflammation, obesity, and smoking. 2 Although age-adjusted incidence rates may be declining, the prevalence of AVS is increasing in the Western society due to aging and increasing life expectancy of the population. 3 Aortic valve stenosis is associated with significant morbidity and mortality, especially in the presence of symptoms (exertion dyspnoea, heart failure, syncope, or angina), or echocardiographic signs of left ventricular remodelling secondary to chronic pressure overload (increased left atrial size, hypertrophy, and reduced ejection fraction). 4 To date, the only effective treatment with documented survival benefit in symptomatic patients with severe AVS is surgical aortic valve replacement (AVR; open heart surgery or transcatheter). 5, 6 Because AVS is strongly related to aging and atherosclerosis, it has been suggested that disease progression may be attenuated by anti-atherosclerotic therapies, 7, 8 but results from randomized trials of lipid lowering therapy (statins 6 ezetimibe vs. placebo) in patients with mild to moderate AVS have been disappointing. 9, 10 Alternative treatment strategies to prevent or improve symptoms, AVR, and mortality in patients with AVS are therefore warranted. Means to attenuate left ventricular remodelling in AVS might be of symptomatic and prognostic benefit, as it poses an independent risk factor for mortality in AVS. 4 In this context, use of renin-angiotensin converting enzyme inhibitors (RASi) has been documented to attenuate cardiac remodelling in patients with heart failure or myocardial infarction accompanied by reduced left ventricular ejection fraction and it is plausible that a similar relation may exist for AVS, but this is not well investigated. Indeed, use of RASi has been considered relatively unsafe in AVS due to concern about its vasodilator effect with possible adverse physiological consequences. Accordingly, the number of published randomized trials of RASi in AVS patients has been limited and the haemodynamic and prognostic benefits of RASi are still unsure. We conducted a systematic literature search and metaanalysis of randomized and observational studies to evaluate whether RASi are safe, may have beneficial effects on the valvular and left ventricular haemodynamics, and may translate into fewer adverse clinical events in patients with AVS.
Methods Design
Systematic review and meta-analysis.
Search strategy
The analysis was conducted according to the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) guidelines and also complied with the MOOSE checklist. 11 The search was conducted in the electronic databases PubMed, EMBASE, and Cochrane library for all published studies that examined the effect of RASi [angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor-2 blocker] in patients with AVS.
The following keywords in different combinations were used: aortic stenosis, aortic valve, ACEi. All relevant published reviews on this topic were also identified and their reference lists were screened. Reference lists of the retrieved articles were screened as well. The literature search was without restrictions and was conducted up to 1 April 2016.
Study eligibility
Randomized controlled trials (RCT) and observational studies, reporting the effect of RASi therapy on AVS at baseline and after a follow-up period, were considered eligible to inclusion. Eligible studies should also provide number of all-cause deaths and AVR. Moreover, data on echocardiographic valvular peak aortic jet velocity (PAJV), change in left ventricular mass index (LVMI), and change in systolic blood pressure (SBP) in patients receiving RASi vs. no-RASi were collected whenever available. The echocardiographic inclusion criteria included a PAJV value of at least 2 m/s. Both symptomatic and asymptomatic populations were included.
Data extraction
Demographic and methodological data, number of all-cause deaths and AVR, means and SD of PAJV and SBP were extracted from each study.
No individual level data were accessed. Appropriate data were extracted both from text and if necessary from graphs or were calculated using propagation of errors for means and SD. In order to obtain homogeneous follow-up for the different studies, 4-year follow-up data were extracted from the study by Capoulade et al. 12 If necessary, authors of the published studies were contacted concerning supplementary data.
Two authors (C. A. and J.A.) independently conducted the search process and data extraction. Any conflict was resolved by consensus.
Statistic
The reported numbers of deaths and AVR in RASi groups compared with the corresponding numbers in controls were pooled together providing the overall risk ratio (RR) with 95% confidence interval (CI). Weighted mean difference method was used for pooling the annual change in PAJV (m/s). We used weighted fixed or random effects model depending on data heterogeneity and sizes of studies as appropriate. Heterogeneity was tested using X 2 method (with a P-value <0.05 considered significant) and I 2 -statistic. The I 2 (measured as 0-100%) indicated the percentage of variation in the study results attributed to between-study heterogeneity rather than sampling error. A value of I 2 above 20% was considered significant. For the estimated overall RR, a two-sided P-value <0.05 was considered significant. The meta-analysis package of the statistic software program STATA version 13 (STATA Corporation, Lakeway Drive, College Station, TX, USA) was used for all analyses.
Results

Results of the search
The results of the search are shown in Figure 1 . Finally, eight studies were eligible for inclusion in the qualitative evaluation and quantitative synthesis.
Characteristics of the studies and populations
Characteristics of the included studies and patients are shown in Table 1 . Three of the eight included studies were RCT [13] [14] [15] and five were nonrandomized observational studies. 12, [16] [17] [18] [19] One observational study was a retrospective analysis of a RCT. 16 A total of 3869 patients received RASi and 4894 did not. The range of follow-up period was between 1 and 4.3 years. The demographic characteristics of patients are shown in Table 2 .
In brief, a little more than half of the patients were men, the majority had hypertension, and most patients had preserved ejection fraction.
Meta-analysis of the effect of reninangiotensin system inhibitors on peak aortic jet velocity
Pooling the mean annual change in PAJV among patients receiving RASi vs. patients who did not receive RASi using random effects model resulted in a weighted mean difference of À0.01(95% CI; À0.02, 0.00) in favour of the RASi group, P-value ¼ 0.07 ( Figure 2) . The studies were homogeneous (P-value ¼ 0.374 for heterogeneity), and had insignificant variation (I 2 ) of 5.8%. The study by Bang was dominating regardless of the type of analysis model used (fixed or random). 16 Meta-analysis of the effect of reninangiotensin system inhibitors on allcause mortality and AVR ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AVR, aortic valve replacement; BP, blood pressure; DB, double blind; Non-R obs., nonrandomized observational; PAJV, peak aortic jet velocity; RCT, randomized controlled trial.
Screening Eligibility
Records identified through database searching (n= 280) (P ¼ 0.0001 for heterogeneity) and with significant variation I 2 ¼ 89%.
There were no reported adverse hypotensive or haemodynamic effects. Two studies reported significant reduction in LVMI, 13, 16 but the reported data were not eligible for a meta-analysis. Four studies reported changes in aortic valve area, but these measures were too heterogeneous precluding a meta-analysis (one reported changes after only 3 months of follow-up, one reported changes in aortic valve area as indexed to body surface area, and one was based on magnetic resonance imaging measures). 13, 16 However, none of the studies reported a significant change in aortic valve areal. 13, 16 These studies provided no published data of subgroups stratified by degree of AVS measured as aortic valve area or PAJV in order to conduct sub-analyses comparing the effect of RASi on patients with severe vs. mild/moderate AVS.
Discussion
The results of the current meta-analysis suggested that RASi are safe to use in AVS (as evident by no significant increase in mortality risk). It may or may not be effective in reducing symptoms (the former suggested by the reduced need for AVR surgery, although the decision of performing AVR surgery may be multifactorial and not solely based on symptoms). Moreover, the results suggested overall modest effects of RASi administration on blood pressures (average À2 mmHg with RASi), but with substantial variability, likely due to differences in timing of measurements and patient characteristics. Yet, overall, our search revealed rather limited evidence on the outcomes associated with RASi in patients with AVS, because most studies were non-randomized and therefore posed an inherited limitation with regards to the ability to accurately control for factors underlying treatment decision (e.g. kidney function, aortic stenosis severity, left ventricular anatomy and function, and symptoms). However, the observational and clinical randomized trials reported non-differential associations for most of the study endpoints (as evident by insignificant heterogeneity tests), suggesting that residual confounding of the observational studies may be limited, although the sample sizes from RCT were small. Aortic valve stenosis exerts a chronic high afterload on the left ventricular wall, resulting in a compensatory high preload and myocyte stretching, hypertrophy, and fibrosis. According to the Starling mechanism, a high preload is warranted to overcome the high afterload (to ensure a high cardiac output) and this has been the reason for the relative contraindication of RASi in AVS (i.e. it may lead to hypotension and lowered coronary perfusion). 20 However, the longterm consequences of a high preload (i.e. left ventricular hypertrophy and fibrosis) are adverse and fibrosis is an important and irreversible risk factor for mortality after AVR. 21, 22 Hypothesis generating evidence that RASi could have important counteracting properties on left ventricular hypertrophy and fibrosis in AVS initially came from experimental animal models. Rats that underwent banding of the ascending aorta (mimicking some of the same adverse effects associated with aortic stenosis on the left ventricle through high afterload) experienced substantially increased filling pressure and left ventricular concentric hypertrophy, followed by left ventricular dilation and lowered systolic ejection fraction. 23 Notably, RASi administration was demonstrated to lower the left ventricular wall stress, attenuate left ventricular dilation, and preserve ejection fraction, compared with no RASi administration. 23 Similar effects of RASi have been reported in other studies of rats undergoing aortic banding, 24 and of rats with AVS, in whom an additional survival benefit has been documented with RASi treatment. 25 Despite that animal models suggested cardioprotective effects of RASi more than 20 years ago, RCT have been historically sparse. The recent study by Dalsgaard et al. 15 on humans (n ¼ 44) suggested that short-term administration (8 weeks) of trandolapril 2 mg had no adverse impact on exercise capacity compared with placebo in patients with severe AVS (valve area <1 cm 2 ), but in contrast it lowered N-terminal pro-B-type natriuretic peptide concentrations and left ventricular end systolic volume, which may suggest improved long-term outcomes with RASi among asymptomatic patients. The hypothesis was further tested by Bull et al. 13 who recently reported that 1-year administration of 10 mg ramipril daily vs. placebo in asymptomatic patients with moderate to severe AVS (n ¼ 100 In favor of RASi In favor of no-RASi Figure 2 Forest plot of the meta-analysis of mean annual change in peak aortic velocity (m/s) during follow-up. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; RASi, renin-angiotensin system inhibitor; WMD, weighted mean difference. In addition to the putative protective effects of RASi on left ventricular remodelling and function, research has suggested that the angiotensin-converting enzyme is present in sclerotic and stenotic lesions of the aortic valve (possibly delivered by low-density lipoprotein particles), but not in normal valves, 27 and that use of RASi may attenuate the progression of aortic valve calcification. 28 We did not further evaluate this premise, as data were sparse, but it is possible that such mechanisms may also have contributed to the observed lowered need for AVR surgery in RASi treatment.
Limitations
Our analyses were based on published studies only. A search at clinicaltrials.gov revealed a few more registered clinical trials aiming to investigate the outcomes associated with RAS inhibitors in AVS, but we were unfortunately not able to include these in our analyses. The echocardiographic measures of the various studies were collected based on local institutional protocols and were not harmonized for this study, which may have affected our results. Moreover, some of the included studies were based on patients with a PAJV of 2 m/s, which corresponds to mild-moderate aortic stenosis only. Thus, the evidence addressing the effect of RASi in more severe AVS is limited. Within this context, most of the studies also only included patients without systolic dysfunction (or very few patients with systolic dysfunction) and extrapolation of the findings to patients with impairments in systolic function can therefore not be done. Also, some patients with aortic stenosis may have had concomitant aortic insufficiency, which may or may not have contributed to the improvements observed with RASi treatment. Moreover, the randomized clinical trials were too small and of too short follow-up to separately perform meaningful meta-analyses of hard endpoints. Finally, we did not investigate whether RASi may or may not also have influenced the risk of atherosclerotic events. 29 Owing to sparse data and potential biases, including selection bias of the observational studies, the results of this meta-analysis should be interpreted cautiously.
Clinical implications and future perspectives
Based on published literature, RASi appear to be safe to use and perhaps effective in reducing need of AVR surgery in patients with AVS and a preserved left ventricular ejection fraction. Thus, current evidence does not support that AVS should be regarded a contraindication for continuation of RASi in patients already in treatment (for other important indications such as hypertension or heart failure).
Further randomized clinical trials are warranted to address whether administration of RASi to treatment-naïve patients with AVS may prevent disease progression, delay AVR surgery need, and lower the risk of mortality. These questions are of clinical importance, given the burden of AVS in the Western world, and should hence be a research priority.
Conclusions
In current clinical practice (based on published literature), use of RASi appears to be safe in patients with AVS. It is possible that RASi may reduce the need for AVR, but the evidence is overall weak. Large-scale randomized clinical trials are warranted to address whether prescription of RASi to treatment-naïve patients may prevent disease progression, delay AVR surgery need, and lower the risk of mortality.
